指南与共识食管胃疾病与幽门螺杆菌胃肠动力与功能性疾病消化道肿瘤与早癌

AGA临床实践更新:免疫功能紊乱与感染所致食管功能障碍专家评述

AGA Clinical Practice Update on Esophageal Dysfunction Due to Disordered Immunity and Infection: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2024-10-22

美国胃肠病学会(AGA)发布专家评述,针对免疫介导和感染性食管疾病提供10条最佳实践建议,涵盖系统性免疫疾病、感染、嗜酸性粒细胞性食管炎、淋巴细胞性食管炎、结缔组织病及克罗恩病的食管表现,强调提高警惕以减少诊断延迟和不必要检查。

要点

  • 胃肠科医生应认识系统性免疫和感染疾病的食管表现,以减少诊断延迟。
  • 感染性食管炎治疗无效时,应评估难治性感染或其他免疫功能障碍原因。
  • 嗜酸性粒细胞性食管炎组织学缓解后仍有症状者,可能发生动力障碍,需进一步评估。

核心结论

  • 认识导致食管功能障碍的局部和系统性过程,可聚焦治疗并减少不必要检查,从而改善患者结局。

研究设计与样本

  • 本专家评述由AGA研究所临床实践更新委员会(CPUC)和AGA理事会委托并批准,经CPUC内部同行评议和《Clinical Gastroenterology and Hepatology》标准外部同行评议。
  • 最佳实践建议来自已发表文献综述和专家意见,未进行系统评价,因此不建议对证据质量或推荐强度进行正式评级。

主要发现

  • 感染性和免疫介导的食管疾病常被低估和诊断不足,可导致食管功能障碍和重复检查的医疗费用。
  • 食管功能障碍可源于活动性局部感染和免疫介导疾病(如念珠菌等),或弥漫性免疫介导疾病或感染(如系统性硬化、结缔组织病、神经系统疾病)的器官特异性表现。
  • 这些情况有时可导致神经肌肉功能障碍和继发性食管动力障碍。

关键数值与推荐

  • 最佳实践建议1:胃肠科医生应认识系统性免疫和感染疾病的食管表现,以减少诊断延迟;临床医生应识别患者食管症状的炎症或感染风险,并排查这些疾病。
  • 最佳实践建议2:一旦确定食管感染,临床医生应识别伴随体征/症状是否提示免疫抑制导致更系统性感染;感染病专家会诊有助于指导适当治疗。
  • 最佳实践建议3:感染性食管炎治疗后症状未改善,应评估难治性感染或其他潜在食管和免疫功能障碍原因。
  • 最佳实践建议4:嗜酸性粒细胞性食管炎(EoE)患者组织学和内镜下疾病缓解但仍持续食管功能障碍症状时,临床医生应意识到部分EoE患者可能发生动力障碍,可能需要进一步评估食管动力。
  • 最佳实践建议6:高嗜酸性粒细胞血症(绝对嗜酸性粒细胞计数[AEC] >1500 cells/uL)伴食管症状者,考虑进一步检查非EoE嗜酸性粒细胞性胃肠病、高嗜酸性粒细胞综合征和嗜酸性肉芽肿性多血管炎(EGPA);过敏/免疫学会诊有助于指导诊断和治疗。

临床怎么用

  • 临床医生在初始评估时应考虑继发性贲门失弛缓症的感染和炎症原因,询问近期COVID感染史、恰加斯病风险及嗜酸性疾病症状或体征。
  • 淋巴细胞性食管炎组织学和内镜特征者,可考虑质子泵抑制剂治疗或吞咽局部皮质类固醇及必要时食管扩张。
  • 系统性硬化(SSc)、混合性结缔组织病(MCTD)、系统性红斑狼疮(SLE)或干燥病患者,食管症状可因食管肌层受累导致动力障碍和/或下食管括约肌功能不全;SSc或MCTD患者功能障碍程度常尤其显著。
  • 克罗恩病患者少数可出现食管受累,表现为炎症、狭窄或瘘管形成,组织学见肉芽肿;食管表现倾向于发生在活动性肠道疾病患者中。
  • 扁平苔藓或大疱性疾病患者可因内镜下可见食管黏膜受累出现吞咽困难;食管扁平苔藓尤其可无皮肤受累,且食管组织病理学定义困难。

局限性

  • 未进行系统评价,因此不建议对证据质量或推荐强度进行正式评级。
  • 最佳实践建议来自已发表文献综述和专家意见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

METHODS: This expert review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. These Best Practice Advice (BPA) statements were drawn from a review of the published literature and from expert opinion. Since systematic reviews were not performed, these BPA statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. DESCRIPTION: Infectious and immune-mediated esophageal disorders are poorly understood and often under-diagnosed conditions that lead to esophageal dysfunction and health care costs due to repeated procedures and a lack of understanding of their etiology and pathogenesis. Without a high index of suspicion, these disorders may be overlooked. Esophageal dysfunction may arise from active, localized infection and immune-mediated disease (ie, candida, etc.) or from an organ-specific manifestation of a more diffuse immune-mediated disease or infection (ie, systemic sclerosis, connective tissue disease, neurologic disease). These conditions can sometimes lead to neuromuscular dysfunction and subsequent esophageal dysmotility. Awareness of local and systemic processes that lead to esophageal dysfunction will improve patient outcomes by focusing therapeutics and limiting unnecessary procedures. Therefore, the purpose of this AGA Clinical Practice Update Expert Review is to provide BPA on diagnostic considerations of immune-mediated disorders that should be considered when encountering patients with dysphagia, heartburn, and odynophagia. Best Practice Advice Statements: BEST PRACTICE ADVICE 1: Gastroenterologists should be aware of the esophageal manifestations of systemic immunologic and infectious diseases to reduce diagnostic delay. Clinicians should identify if there are risks for inflammatory or infectious possibilities for a patient's esophageal symptoms and investigate for these disorders as a potential cause of esophageal dysfunction. BEST PRACTICE ADVICE 2: Once esophageal infection is identified, clinicians should identify whether accompanying signs/symptoms suggest immunocompromise leading to a more systemic infection. Consultation with an infectious disease expert will aid in guiding appropriate treatment. BEST PRACTICE ADVICE 3: If symptoms do not improve after therapy for infectious esophagitis, evaluation for refractory infection or additional underlying sources of esophageal and immunologic dysfunction should be performed. BEST PRACTICE ADVICE 4: In individuals with eosinophilic esophagitis (EoE) who continue to experience symptoms of esophageal dysfunction despite histologic and endoscopic disease remission, clinicians should be aware that some patients with EoE may develop motility disorders. Further evaluation of esophageal motility may be warranted. BEST PRACTICE ADVICE 5: In individuals with histologic and endoscopic features of lymphocytic esophagitis, clinicians should consider treatment of lymphocytic-related inflammation with proton-pump inhibitor therapy or swallowed topical corticosteroids and as needed esophageal dilation. BEST PRACTICE ADVICE 6: In patients who present with esophageal symptoms in the setting of hypereosinophilia (absolute eosinophil count [AEC] >1500 cells/uL), consider further work-up of non-EoE eosinophilic gastrointestinal (GI) disease, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis (EGPA). Consultation with allergy/immunology may help guide further diagnostic work-up and treatment. BEST PRACTICE ADVICE 7: In individuals with rheumatologic diseases of systemic sclerosis (SSc), mixed connective tissue disease (MCTD), systemic lupus erythematosus (SLE), or Sjogren's disease, clinicians should be aware that esophageal symptoms can occur due to involvement of the esophageal muscle layer, resulting in dysmotility and/or incompetence of the lower esophageal sphincter. The degree of dysfunction is often especially significant in those with SSc or MCTD. BEST PRACTICE ADVICE 8: In individuals with Crohn's disease, clinicians should be aware that a minority of individuals can develop esophageal involvement from inflammatory, stricturing, or fistulizing changes with granulomas seen histologically. Esophageal manifestations of Crohn's disease tend to occur in individuals with active intestinal disease. BEST PRACTICE ADVICE 9: In individuals with dermatologic diseases of lichen planus or bullous disorders, clinicians should be aware that dysphagia can occur due to endoscopically visible esophageal mucosal involvement. Esophageal lichen planus, in particular, can occur without skin involvement and can be difficult to define on esophageal histopathology. BEST PRACTICE ADVICE 10: Clinicians should consider infectious and inflammatory causes of secondary achalasia during initial evaluation. One should query for any history of recent COVID infections, risks for Chagas disease, and symptoms or signs of eosinophilic disease.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Reddy CA, McGowan E, Yadlapati R, et al. AGA Clinical Practice Update on Esophageal Dysfunction Due to Disordered Immunity and Infection: Expert Review. Clin Gastroenterol Hepatol. 2024. PMID: 39436337. doi:10.1016/j.cgh.2024.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。